Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 13Pancreatic Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Sarcoma, Ewing 2Ovarian Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Prostatic Diseases 1Prostate Cancer Metastatic 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Kidney Neoplasms 1Hepatoblastoma 1Fanconi Anemia, Complementation Group D1 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma 1

Interventions

enzalutamide 7Prednisone 7cabazitaxel 6Radiosurgery 6Docetaxel 5Androgen Antagonists 4Abiraterone Acetate 4XRP6258 2Standard of Care 2talazoparib 1sipuleucel-T 1rucaparib 1pembrolizumab 1olaparib 1gallium 68 PSMA-11 1fludrocortisone acetate 1darolutamide 1apalutamide 1Zuclomiphene 1Radiotherapy, Image-Guided 1Radiotherapy 1Prednisolone 1Positron Emission Tomography Computed Tomography 1Pluvicto 1Midazolam 1Lutetium-177 1Lutetium 1Lenograstim 1LY3023414 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Cancer Metastatic × talazoparib × Genitourinary × Clear all
NCT04824937 2021-04-01

Telaglenastat + Talazoparib In Prostate Cancer

Massachusetts General Hospital

Phase 2 Unknown
30 enrolled
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡